Welcome to the European Association for Cancer Research
Connecting cancer researchers together
EACR-Boehringer Ingelheim Conference: Drugging and Regulating the MAP Kinase Pathway
Virtual Event, Worldwide : 11 - 12 February 2025
Scientific programme
To download and print the programme, use the links below.
Listed times are in Central European Time (CET)
WELCOME TO DAY ONE
Chair: Marco Hofmann
OPENING KEYNOTE LECTURE
Piro Lito Memorial Sloan Kettering Cancer Center, USA
'A ‘new’ old approach to inactivate RAS'
Q&A 13:40-13:55
Miriam Molina Arcas Francis Crick Institute, UK
'Rational approaches to combine KRAS inhibitors and immunotherapies in lung cancer'
Q&A 14:15-14:25
Saptaparna Mukherjee Francis Crick Institute, UK
Proffered Paper 1: 'MYC and KRASG12C Cooperation Drives Immune-Evasive Tumour Progression in Lung Adenocarcinoma'
Q&A 14:35-14:40
REFRESHMENT BREAK
Chair: Anna Obenauf
Sandra Misale John Hopkins University, USA
'Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma'
Q&A 15:20-15:30
Robert Kortum Uniformed Services University, USA
Proffered Paper 2: 'SOS1 inhibition enhances the efficacy of and delays resistance to oncogene-targeted therapies in lung adenocarcinoma'
Q&A 15:40-15:45
Mallika Singh Revolution Medicines, USA
'Targeting the Oncogenic State of RAS with Tri-Complex Inhibitors'
Q&A 16:05-16:15
POSTER SPOTLIGHTS
TRANSITION BREAK
VIRTUAL POSTER SESSION ONE
Scheduled to end at 17:35 CET
Listed times are in Central European Time (CET)
VIRTUAL POSTER SESSION TWO
Scheduled to end at 13:30 CET
WELCOME TO DAY TWO
Chair: Chiara Ambrogio
Marco Hofmann Boehringer Ingelheim, Austria
'Targeting the RAS Signaling Pathway: Inhibitors and Mechanisms of Resistance'
Q&A 14:25-14:35
Alberto Bardelli University of Torino, Italy
'Adaptive cancer mutability in response to targeted therapies'
Q&A 14:55-15:05
Christian Umkehrer Boehringer Ingelheim, Austria
Proffered Paper 3: 'Dissecting the clonal evolution of resistance to KRAS inhibitors through genetic barcoding and scRNAseq'
Q&A 15:15-15:20
REFRESHMENT BREAK
Chair: René Bernards
Marina Pasca di Magliano University of Michigan Medicine School, USA
'Oncogenic KRAS mediated regulation of the pancreatic cancer microenvironment'
Q&A 16:00-16:10
Gonzalo Aizpurua Spanish National Cancer Research Centre, Spain
Proffered Paper 4: 'Identifying RAF1 degraders as a therapeutic approach in KRAS-driven lung tumors'
Q&A 16:20-16:25
CLOSING KEYNOTE LECTURE
Colin Lindsay Manchester Cancer Research Centre, UK
'Bedside to bench to bedside again: leveraging KRAS precision medicine for optimum clinical benefit'
Q&A 16:55-17:10
DISCUSSION SESSION
René Bernards, Anna Obenauf, Marco Hofmann & Chiara Ambrogio
'New challenges for old therapeutic targets: What's next?'
SUMMARY AND CLOSE
